Purine analog mechanisms

Purine analog mechanisms refer to the means by which purine analogues, a class of antimetabolite drugs, disrupt cellular proliferation by mimicking endogenous purines (adenine and guanine) and interfering with DNA and RNA metabolism. These compounds are taken up by cells and phosphorylated into active nucleotides, which can then: - Inhibit critical enzymes involved in purine synthesis and nucleotide metabolism (such as IMP dehydrogenase), - Become incorporated into nucleic acids, causing faulty DNA/RNA and resulting in cytotoxicity, - Ultimately lead to inhibition of DNA replication, cell cycle arrest, and apoptosis, especially in rapidly proliferating cells such as malignant hematopoietic or immune cells. Clinical use includes treatment of cancers (especially leukemias and lymphomas), some autoimmune and inflammatory disorders, and infections (research ongoing). The molecular and clinical effects of purine analog drugs are distinct yet mechanistically similar, involving cellular uptake, activation by kinases, and inhibition or interruption of DNA/RNA synthesis and repair. Note: Since "Purine analog mechanisms" is not a unique drug target molecule/receptor but a collective term for the class's pharmacological actions, it is not a target by strict molecular pharmacology definitions and should be corrected for database curation purposes.

Other names

Purine analog mechanismPurine analogue mechanism

Inhibition of DNA polymerases, Inhibition of ribonucleotide reductase, Incorporation into DNA/RNA causing chain termination or instability, Inhibition of enzymes in purine metabolism (e.g., IMP dehydrogenase, DNA/RNA polymerases)